Incidence of omental metastasis in uterine serous carcinoma: a systematic review and meta-analysis

Xu, Hui; Cui, Shuang-Shuang; Ran, Lin; Liu, Yi; Hu, Cui; Xu, Yu; Tian, Yifei

doi:10.1016/j.jogoh.2022.102395

Cited by 6 publications

(5 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A staging operation is necessary to establish this category. A significant proportion (≥40%) of high‐grade tumors (particularly serous carcinomas) assumed to be limited to a polyp or the endometrium have occult lymph node and/or peritoneal involvement when appropriately staged and hence are actually Stage III disease 55–57 …”

Section: Figo Staging Of Endometrial Cancermentioning

confidence: 99%

“…A significant proportion (≥40%) of high-grade tumors (particularly serous carcinomas) assumed to be limited to a polyp or the endometrium have occult lymph node and/or peritoneal involvement when appropriately staged and hence are actually Stage III disease. [55][56][57] Low-grade EECs are associated with a good prognosis when they are limited to the uterine corpus and there is no LVSI or focal LVSI. 2,22,[58][59][60][61][62] There is a subset of patients with low-grade endometrioid carcinomas involving the endometrium and the ovaries, which are associated with a good prognosis.…”

Section: Stage Imentioning

confidence: 99%

See 1 more Smart Citation

FIGO staging of endometrial cancer: 2023

Berek

Matías‐Guiu

Creutzberg

et al. 2023

Intl J Gynecology & Obste

355

112

View full text Add to dashboard Cite

Introduction: Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009. Substantially more outcome and biological behavior data are now available regarding the several histological types. Molecular and genetic findings have accelerated since the publication of The Cancer Genome Atlas (TCGA) data and provide improved clarity on the diverse biological nature of this collection of endometrial cancers and their differing prognostic outcomes. The goals of the new staging system are to better define these prognostic groups and create substages that indicate more appropriate surgical, radiation, and systemic therapies. Methods: The FIGO Women's Cancer Committee appointed a Subcommittee on Endometrial Cancer Staging in October 2021, represented by the authors. Since then, the committee members have met frequently and reviewed new and established evidence on the treatment, prognosis, and survival of endometrial cancer. Based on these data, opportunities for improvements in the categorization and stratification of these factors were identified in each of the four stages. Data and analyses from the molecular and histological classifications performed and published in the recently developed ESGO/ESTRO/ESP guidelines were used as a template for adding the new subclassifications to the proposed molecular and histological staging system. Results: Based on the existing evidence, the substages were defined as follows: Stage I (IA1): non-aggressive histological type of endometrial carcinoma limited to a polyp or confined to the endometrium; (IA2) non-aggressive histological types of endometrium involving less than 50% of the myometrium with no or focal lymphovascular space invasion (LVSI) as defined by WHO criteria; (IA3) low-grade endometrioid carcinomas limited to the uterus with simultaneous low-grade endometrioid ovarian involvement; (IB) non-aggressive histological types involving 50% or more of the myometrium with no LVSI or focal LVSI; (IC) aggressive histological types, i.e. serous,

show abstract

Section: Figo Staging Of Endometrial Cancermentioning

confidence: 99%

Section: Stage Imentioning

confidence: 99%

FIGO staging of endometrial cancer: 2023

Berek

Matías‐Guiu

Creutzberg

et al. 2023

Intl J Gynecology & Obste

355

112

View full text Add to dashboard Cite

show abstract

“…A staging operation is necessary to establish this category. A significant proportion (≥40%) of high-grade tumors (particularly serous carcinomas) assumed to be limited to a polyp or the endometrium have occult lymph node and/or peritoneal involvement when appropriately staged and hence are actually Stage III disease [ 55 56 57 ].…”

Section: Figo Staging Of Endometrial Cancermentioning

confidence: 99%

FIGO staging of endometrial cancer: 2023

et al. 2023

View full text Add to dashboard Cite

Introduction Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009. Substantially more outcome and biological behavior data are now available regarding the several histological types. Molecular and genetic findings have accelerated since the publication of The Cancer Genome Atlas (TCGA) data and provide improved clarity on the diverse biological nature of this collection of endometrial cancers and their differing prognostic outcomes. The goals of the new staging system are to better define these prognostic groups and create substages that indicate more appropriate surgical, radiation, and systemic therapies. Methods The FIGO Women's Cancer Committee appointed a Subcommittee on Endometrial Cancer Staging in October 2021, represented by the authors. Since then, the committee members have met frequently and reviewed new and established evidence on the treatment, prognosis, and survival of endometrial cancer. Based on these data, opportunities for improvements in the categorization and stratification of these factors were identified in each of the four stages. Data and analyses from the molecular and histological classifications performed and published in the recently developed ESGO/ESTRO/ESP guidelines were used as a template for adding the new subclassifications to the proposed molecular and histological staging system. Results Based on the existing evidence, the substages were defined as follows: Stage I (IA1): non-aggressive histological type of endometrial carcinoma limited to a polyp or confined to the endometrium; (IA2) non-aggressive histological types of endometrium involving less than 50% of the myometrium with no or focal lymphovascular space invasion (LVSI) as defined by WHO criteria; (IA3) low-grade endometrioid carcinomas limited to the uterus with simultaneous low-grade endometrioid ovarian involvement; (IB) non-aggressive histological types involving 50% or more of the myometrium with no LVSI or focal LVSI; (IC) aggressive histological types, i.e. serous, high-grade endometrioid, clear cell, carcinosarcomas, undifferentiated, mixed, and other unusual types without any myometrial invasion. Stage II (IIA): non-aggressive histological types that infiltrate the cervical stroma; (IIB) non-aggressive histological types that have substantial LVSI; or (IIC) aggressive histological types with any myometrial invasion. Stage III (IIIA): differentiating between adnexal versus uterine serosa infiltration; (IIIB) infiltration of vagina/parametria and pelvic peritoneal metastasis; and (IIIC) refinements for lymph node metastasis to pelvic and para-aortic lymph nodes, including micrometastasis and macrometastasis. Stage IV (IVA): locally advanced disease infiltrating the bla...

show abstract

“…However, the necessary condition is the ability to perform ultrastaging of the resected lymph nodes [ 110 ]. Infracolonic omentectomy should only be performed in patients with serous or undifferentiated EC [ 111 ].…”

Section: Ec Treatmentmentioning

confidence: 99%

Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection

Galant,

Krawczyk,

Monist

et al. 2024

IJMS

View full text Add to dashboard Cite

Endometrial cancer (EC) accounts for 90% of uterine cancer cases. It is considered not only one of the most common gynecological malignancies but also one of the most frequent cancers among women overall. Nowadays, the differentiation of EC subtypes is based on immunohistochemistry and molecular techniques. It is considered that patients’ prognosis and the implementation of the appropriate treatment depend on the cancer subtype. Patients with pathogenic variants in POLE have the most favorable outcome, while those with abnormal p53 protein have the poorest. Therefore, in patients with POLE mutation, the de-escalation of postoperative treatment may be considered, and patients with abnormal p53 protein should be subjected to intensive adjuvant therapy. Patients with a DNA mismatch repair (dMMR) deficiency are classified in the intermediate prognosis group as EC patients without a specific molecular profile. Immunotherapy has been recognized as an effective treatment method in patients with advanced or recurrent EC with a mismatch deficiency. Thus, different adjuvant therapy approaches, including targeted therapy and immunotherapy, are being proposed depending on the EC subtype, and international guidelines, such as those published by ESMO and ESGO/ESTRO/ESP, include recommendations for performing the molecular classification of all EC cases. The decision about adjuvant therapy selection has to be based not only on clinical data and histological type and stage of cancer, but, following international recommendations, has to include EC molecular subtyping. This review describes how molecular classification could support more optimal therapeutic management in endometrial cancer patients.

show abstract

Incidence of omental metastasis in uterine serous carcinoma: a systematic review and meta-analysis

Cited by 6 publications

References 57 publications

FIGO staging of endometrial cancer: 2023

FIGO staging of endometrial cancer: 2023

FIGO staging of endometrial cancer: 2023

Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection

Contact Info

Product

Resources

About